Compare Bank of New York Mellon Corp (BNY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Bank of New York Mellon Corp trades at $162.84 (market cap $108.78B), while State Street SPDR S&P Biotech ETF trades at $159.36. The key difference: Bank of New York Mellon Corp pays a 1.38% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| BNY | XBI | |
|---|---|---|
Market Cap | $108.78B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $162.35 | $164.28 |
52-Week Low | $101.00 | $86.92 |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY stock trades at $162.92, up 2.18% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $2.46 beating estimates and consistent revenue growth from $19.76B in 2025 to $21.0B projected for 2026. Analyst sentiment remains positive with 10 buy ratings and a $170.36 consensus price target, supported by recent digital transfer agency expansion and blockchain infrastructure collaborations.
Outlook remains favorable with earnings momentum and digital innovation driving growth, though elevated RSI levels suggest near-term consolidation risk. The stock offers 4.6% upside to consensus target with strong institutional support, balanced by competitive pressures in custody banking and interest rate sensitivity as key monitoring points.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
